AmbioPharm, Inc – FDA 483, Feb 9, 2023
AmbioPharm, Inc. in Beech Island, SC, a peptide-drug substance manufacturer, received a Form 483 with two significant observations. The inspection revealed issues with the QC laboratory's handling of out-of-specification results, including repeated invalidations and re-testing without adequate controls, and a lack of real-time data documentation. Additionally, the firm failed to maintain sufficient control over its water systems, leading to persistent microbial contamination and objectionable organisms in components used for drug substances.
- Office
- Atlanta District Office
- Person
ID · f5b141ab-3baf-4e5b-9481-6e991f46418e
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.